|
FY2015
12 months to Dec 31, 2015
|
|
|---|---|
| Cash flows from operations | |
| Net income | |
| Adjustments | |
| Depreciation and amortization | |
| Deferred income taxes | |
| Share-based compensation expense | |
| Excess tax benefits from share-based compensation | |
| Business optimization (benefits) charges, net | |
| Gain on sale of discontinued operations | |
| Net periodic pension benefit and OPEB cost | |
| Change in fair value of contingent payment liabilities | |
| IPR&D impairment charge | |
| Other | |
| Changes in balance sheet items | |
| Accounts and other current receivables, net | |
| Inventories | |
| Accounts payable | |
| Accrued liabilities | |
| Due to/from Baxter International Inc | |
| Business optimization payments | |
| Other | |
| Net cash provided from operations | |
| Cash flows from investing activities | |
| Capital expenditures | |
| Acquisitions, net of cash acquired | |
| Divestiture of vaccines business | |
| Other investing activities | |
| Net cash used for investing activities | |
| Cash flows from financing activities | |
| Net proceeds from issuance of long-term debt | |
| Payments of obligations | |
| Cash dividends on common stock | |
| Net transactions with Baxter International Inc. | |
| Proceeds and excess tax benefits related to share-based compensation | |
| Other financing activities | |
| Net cash provided from (used for) financing activities | |
| Effect of foreign exchange rate changes on cash and equivalents | |
| Change in cash and equivalents | |
| Cash and equivalents at end of period |
Loading...
